Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
Patient Insights: Colorectal CancerEvent planner and colorectal cancer survivor Kim Hall-Jackson tells us how she hopes to improve rates of diagnosis, Share XPatient Insights: Colorectal Cancerhttps://pharmaphorum.com/views-analysis-patients/patient-insights-colorectal-cancer/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’A new trial has shown for the first time that a combination of three targeted therapies can improve Share XArray, Pierre Fabre bowel cancer therapy ‘could replace chemo’https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/
FDA approves consumer colorectal cancer testThe FDA will allow consumer DNA testing company 23andMe to give customers reports on their risk of hereditary Share XFDA approves consumer colorectal cancer testhttps://pharmaphorum.com/news/fda-approves-consumer-colorectal-cancer-test/
BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
